Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

NCT05506254 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2026-02-05

No results posted yet for this study

Summary

This is a non-interventional long-term follow-up study of patients who have participated in LogicBio studies for the treatment of MMA and received hLB-001

Conditions

  • Methylmalonic Acidemia

Interventions

DRUG

hLB-001

hLB-001 gene therapy

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2037-01-01
Completion
2037-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05506254 on ClinicalTrials.gov